219 related articles for article (PubMed ID: 2469101)
21. Effect of thromboxane A2 synthetase inhibition, singly and combined with thromboxane A2/prostaglandin endoperoxide receptor antagonism, on inositol phospholipid turnover and on 5-HT release by washed human platelets.
de Chaffoy de Courcelles D; De Clerck F
Eur J Pharmacol; 1990 Mar; 188(2-3):161-9. PubMed ID: 2318257
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetic and pharmacodynamic profiles of vapiprost, a selective, long-lasting thromboxane receptor antagonist, after single and multiple oral administration to healthy volunteers.
Uematsu T; Nagashima S; Mizuno A; Hirano K; Nakashima M
J Clin Pharmacol; 1991 Sep; 31(9):815-22. PubMed ID: 1839540
[TBL] [Abstract][Full Text] [Related]
23. Inhibitory effects of the selective thromboxane receptor antagonist BM 13.177 on platelet aggregation, vasoconstriction and sudden death.
Patscheke H; Stegmeier K; Müller-Beckmann B; Sponer G; Staiger C; Neugebauer G
Biomed Biochim Acta; 1984; 43(8-9):S312-8. PubMed ID: 6097235
[TBL] [Abstract][Full Text] [Related]
24. Prostaglandin H2/thromboxane A2 pathway in platelet aggregation and activity of Dahl salt-sensitive rat--a sulotroban study.
Somova L
Methods Find Exp Clin Pharmacol; 1996 Jun; 18(5):309-13. PubMed ID: 8817465
[TBL] [Abstract][Full Text] [Related]
25. Prostaglandin I2 mediates contraction and relaxation of vascular smooth muscle.
Williams SP; Dorn GW; Rapoport RM
Am J Physiol; 1994 Aug; 267(2 Pt 2):H796-803. PubMed ID: 8067435
[TBL] [Abstract][Full Text] [Related]
26. Investigation on a selective non-prostanoic thromboxane antagonist, BM 13.177, in human platelets.
Patscheke H; Stegmeier K
Thromb Res; 1984 Feb; 33(3):277-88. PubMed ID: 6424261
[TBL] [Abstract][Full Text] [Related]
27. Regulation of human platelet activation--analysis of cyclooxygenase and cyclic AMP-dependent pathways.
Krishnamurthi S; Westwick J; Kakkar VV
Biochem Pharmacol; 1984 Oct; 33(19):3025-35. PubMed ID: 6091666
[TBL] [Abstract][Full Text] [Related]
28. Studies on the effects of agonists and antagonists on platelet shape change and platelet aggregation in whole blood.
Sanderson HM; Heptinstall S; Vickers J; Lösche W
Blood Coagul Fibrinolysis; 1996 Mar; 7(2):245-8. PubMed ID: 8735830
[TBL] [Abstract][Full Text] [Related]
29. Characterization of thromboxane A2/prostaglandin H2 (TXA2/PGH2) receptors of rat platelets and their interaction with TXA2/PGH2 receptor antagonists.
Hanasaki K; Arita H
Biochem Pharmacol; 1988 Oct; 37(20):3923-9. PubMed ID: 2973322
[TBL] [Abstract][Full Text] [Related]
30. Effects of a novel non-carboxylic thromboxane A2 receptor antagonist (BM-531) derived from torasemide on platelet function.
Dogné JM; de Leval X; Neven P; Rolin S; Wauters J; David JL; Delarge J; Massereel B
Prostaglandins Leukot Essent Fatty Acids; 2000 May; 62(5):311-7. PubMed ID: 10883063
[TBL] [Abstract][Full Text] [Related]
31. Characterization of prostaglandin and thromboxane receptors expressed on a megakaryoblastic leukemia cell line, MEG-01s.
Watanabe T; Yatomi Y; Sunaga S; Miki I; Ishii A; Nakao A; Higashihara M; Seyama Y; Ogura M; Saito H
Blood; 1991 Nov; 78(9):2328-36. PubMed ID: 1718495
[TBL] [Abstract][Full Text] [Related]
32. Thromboxane A2-mediated shape change: independent of Gq-phospholipase C--Ca2+ pathway in rabbit platelets.
Ohkubo S; Nakahata N; Ohizumi Y
Br J Pharmacol; 1996 Mar; 117(6):1095-104. PubMed ID: 8882602
[TBL] [Abstract][Full Text] [Related]
33. AH6809, a prostaglandin DP-receptor blocking drug on human platelets.
Keery RJ; Lumley P
Br J Pharmacol; 1988 Jul; 94(3):745-54. PubMed ID: 2460179
[TBL] [Abstract][Full Text] [Related]
34. TRA-418, a novel compound having both thromboxane A(2) receptor antagonistic and prostaglandin I(2) receptor agonistic activities: its antiplatelet effects in human and animal platelets.
Yamada N; Miyamoto M; Isogaya M; Suzuki M; Ikezawa S; Ohno M; Otake A; Umemura K
J Thromb Haemost; 2003 Aug; 1(8):1813-9. PubMed ID: 12911598
[TBL] [Abstract][Full Text] [Related]
35. Computer-aided molecular modeling of a thromboxane receptor antagonist S-145 and its related compounds.
Ezumi K; Yamakawa M; Narisada M
J Med Chem; 1990 Apr; 33(4):1117-22. PubMed ID: 2138675
[TBL] [Abstract][Full Text] [Related]
36. Actions of the E2-isoprostane, 8-ISO-PGE2, on the platelet thromboxane/endoperoxide receptor in humans and rats: additional evidence for the existence of a unique isoprostane receptor.
Longmire AW; Roberts LJ; Morrow JD
Prostaglandins; 1994 Oct; 48(4):247-56. PubMed ID: 7878192
[TBL] [Abstract][Full Text] [Related]
37. Primate vascular responses to octimibate, a non-prostanoid agonist at the prostacyclin receptor.
Merritt JE; Brown AM; Bund S; Cooper DG; Egan JW; Hallam TJ; Heagerty AM; Hickey DM; Kaumann AJ; Keen M
Br J Pharmacol; 1991 Jan; 102(1):260-6. PubMed ID: 2043927
[TBL] [Abstract][Full Text] [Related]
38. Pharmacological profile of BMS 180,291: a potent, long-acting, orally active thromboxane A2/prostaglandin endoperoxide receptor antagonist.
Ogletree ML; Harris DN; Schumacher WA; Webb ML; Misra RN
J Pharmacol Exp Ther; 1993 Feb; 264(2):570-8. PubMed ID: 8437108
[TBL] [Abstract][Full Text] [Related]
39. Pharmacological characterization of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptor.
Yu SM; Wu TS; Teng CM
Br J Pharmacol; 1994 Mar; 111(3):906-12. PubMed ID: 8019768
[TBL] [Abstract][Full Text] [Related]
40. Two phasic generation of thromboxane A2 by the action of collagen on rat platelets.
Hanasaki K; Nakano T; Arita H
Thromb Res; 1987 May; 46(3):425-36. PubMed ID: 2955543
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]